President Donald Trump has long bantered about GLP-1s, the breakthrough medicines that have changed care for diabetes and obesity. Sometimes he calls them “the fat drug.” In an interview with the The ...

Eli Lilly on May 21 said its experimental weight-loss shot retatrutide delivered dramatic weight loss in a late-stage study of people with obesity. Lilly said people on the next-generation weight loss ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO ...

NEW YORK, May 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday its experimental obesity drug helped patients lose more ‌than 28% of their weight over a year and a half in a key trial ...

Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing ...

Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight, about 85 pounds, in a late-stage clinical trial, the drugmaker said in a news ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said. By Gina Kolata and Rebecca Robbins An experimental shot helped participants ...

There's no question Eli Lilly has been the most active biopharma dealmaker of recent months, but even the billions the pharma already spent on acquisitions hasn't exhausted its appetite. The latest ...

Eli Lilly has snagged Engage Biologics, a biotechnology company that aims to deliver genetic medicines without viral payloads, in a deal worth up to $202 million. Lilly said Wednesday it has acquired ...